Language and Motricity in Preterm School Age Children (LAMOPRESCO2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02811029|
Recruitment Status : Unknown
Verified August 2017 by University Hospital, Rouen.
Recruitment status was: Recruiting
First Posted : June 23, 2016
Last Update Posted : August 30, 2017
A total of 40% of neurodevelopmental difficulties have been reported in very premature infants less than 32 weeks of age. The Epipage1 study reported a decreasing prevalence of cerebral palsy (9-6%) but a high prevalence of specific cognitive neurological difficulties and an increase in school failure.
Neurocognitive difficulties are numerous: visuospatial dyspraxia, language disorders, executive function disorders as well as attention and behaviour disorders. Developmental language disorders have been rarely reported in the literature. This originally prompted our request i.e. PHRC 2010 National Multicenter: LAMOPRESCO. For the past 3 years this protocol has studied the language development of children who were born very prematurely, aged 3 and a half years free of cerebral palsy, in particular the impact of a short rehabilitation period, precise, at an early stage, and protocolized on a fundamental sensorimotor language. The principal assessment criterion was the measurement of phonology, the cornerstone of oral and written language in humans. The aim of the present project is an analysis of the effect that this specific language stimulation has on the learning of written language. The hypothesis is that a specific work modifying various aspects of a child's language, during the age of 3 to 4, alters the development of phonological skills in a sustainable way. The acquisition of reading skills is basically dependent on the quality of its phonological components. The randomized study of children up to 8 years of age in a cohort of 150 children (LAMOPRESCO) will permit to confirm or refute this hypothesis. These increasing difficulties have been reported as regards the language understanding of 3 to 15 year old children. It is as if the initial difficulties and weaknesses, which moreover constituted oral language, prevented the use or development of neural networks, which became more complex and required both an oral and written language. Are these elements which constitute phonology, at an early stage, modifiable before the close of the clinically measurable developmental window?
|Condition or disease||Intervention/treatment||Phase|
|Infant, Premature||Behavioral: measurement of phonology||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||165 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Language and Motricity in Preterm School Age Children|
|Study Start Date :||July 2016|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2019|
Experimental: premature infants less than 32 weeks of age
measurement of phonology in premature infants less than 32 weeks of age who participated to LAMOPRESCO-1 study
Behavioral: measurement of phonology
measurement of phonology will be assess using BILO-3, EDA, VS and VL tests
- Evaluation of reading speed [ Time Frame: Day 1 ]Evaluation of reading speed will be assess using silent reading speed test. Patient must read a list of words during 2 minutes. The total number of read words will be analyse to calculate the reading speed.
- Evaluation of syntax level [ Time Frame: Day 1 ]Patient must read a list of words during 2 minutes and select how much words are not correctly written.
- Evaluation of vocabulary level, syntax and understanding [ Time Frame: Day 1 ]Patient must read a list of words during 2 minutes and select how much words are not correctly written.
- Evaluation of understanding level [ Time Frame: Day 1 ]Patient must read a text and then answer oral questions about the history read.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02811029
|Contact: Aude CHAROLLAIS, MDemail@example.com|
|Contact: Julien BLOTfirstname.lastname@example.org|
|Rouen University Hospital||Recruiting|
|Contact: Aude CHAROLLAIS email@example.com|
|Sub-Investigator: Stéphane MARRET, Pr|
|Principal Investigator:||Aude CHAROLLAIS, MD||Rouen University Hospital|